All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The shortage of semiconductor products, such as computer processors, was an artifact of the COVID-19 pandemic, but the shortage has yet to ease, to the detriment of hospitals, device makers and patients. That dilemma surfaced again as the U.S. Department of Commerce met with device makers to discuss the dilemma, which in the views of some still constitutes a crisis of health care.
Drug delivery opportunities are at the heart of Halozyme Therapeutics Inc.’s nearly $1 billion acquisition of Antares Pharma Inc. The deal brings Halozyme an autoinjector platform to complement its Enhanze drug delivery technology, which is designed to reduce hours-long treatments to minutes.
SK Biopharmaceuticals Co. Ltd.'s three-pronged plan for tackling epilepsy is going strong, with lead drug cenobamate for drug-resistant focal-onset seizures nearing the finish line, and earlier-stage programs for a mRNA-based approach and a digital therapeutic in the works.